Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 3Recurrence 2Neoplasms 2Hypersensitivity 2Uterine Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoadjuvant Therapy 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 11Carboplatin 7Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Cetuximab 5Trastuzumab 4Specimen Handling 4Radiotherapy 4Paclitaxel 4Sorafenib 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Goserelin 3Doxorubicin 3Capecitabine 3Biopsy 3sacituzumab govitecan 2darolutamide 2bicalutamide 2Radiotherapy, Intensity-Modulated 2Platinum 2Oxaliplatin 2Leuprolide 2Irinotecan 2Ipilimumab 2Dasatinib 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Salivary Gland Neoplasms × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡